Author(s): Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M ACAC AN
Abstract Share this page
Abstract The routine use of integrase inhibitors in sub-Saharan Africa where HIV-1 non-B viruses predominate is limited, but evaluating their effectiveness on HIV-1 subtypes and CRFs that circulate in this region is essential. We here analyzed 97 integrase sequences from HIV-1 non-B-infected individuals from African countries. Using currently available interpretation algorithms (ANRS, HIVdb, and Rega), we identified the presence of mutations at nine resistance-associated positions including L74M (3.1\%), T97A (9.3\%), K156N (2.1\%), E157Q (5.2\%), G163K (1.0\%), T206S (48.5\%), S230N (1.0\%), D232N (1.0\%), and R236K (1.0\%). All but one (E157Q) were considered as accessory resistant mutation by the algorithms. E157Q identified in 5\% of patients tested (5/97) was selected by the ANRS algorithm as a primary mutation, which alone can confer resistance to raltegravir. These results illustrated the need of further in vitro and clinical studies involving non-B viruses to better understand the real significance of observed mutations and harmonize interpretations.
This article was published in AIDS Res Hum Retroviruses
and referenced in Journal of Antivirals & Antiretrovirals